Device / Technology News

RSS

Cedars-Sinai Neurovascular Center's clinical trial of minimally invasive stenting procedure for TIA

Individuals between 30 and 80 years of age, who have had a transient ischemic attack (TIA) or non-severe stroke within the past 30 days, and who cannot be treated surgically, may be eligible to participate in a Phase III clinical trial of a minimally invasive stenting procedure at the Cedars-Sinai Neurovascular Center. The study will focus specifically on patients who have had an intracranial artery narrowed by at least 70 percent and who are experiencing recurrent strokes or TIAs despite being on anti-clotting medication.

19 Mar 2010

CIO Healthcare Summit to be sponsored by Zanett Healthcare

Zanett Healthcare is pleased to announce that it will sponsor the CIO Healthcare Summit, a leading gathering for CIOs, analysts and industry-thought leaders within healthcare information technology. The CIO Healthcare Summit will be held at the InterContinental Montelucia Resort in Scottsdale, Arizona on May 9-12, 2010.

19 Mar 2010

Maxine Morgan Eyewear unveils comprehensive line of specialized lenses, frames and specialty products

Maxine Morgan Eyewear unveils its comprehensive line of specialized lenses, frames and specialty products with a major presence here at the International Vision Expo East, booth # MS1060, medical science pavilion, in the Jacob K. Javits Convention Center.

19 Mar 2010

Hip-hop and neuroscience

The tweets flew fast and furious at the famous South By Southwest Music, Film, & Interactive Festival in Austin, Texas when "Listen To Your Brain" began playing on the big screen.

19 Mar 2010

White paper describes health and economic burden of diabetes on Americans

PositiveID Corporation announced today that it has published a white paper entitled “Fixing the Black Hole in Diabetes Management,” which describes the health and economic burden of diabetes on Americans and our economy.

19 Mar 2010

Studies reveal increased polyp detection rates with TER during colonoscopy

Two new studies show an increase in polyp detection rates using the Third Eye Retroscope (TER), a retrograde viewing device, during colonoscopy. The first study found that TER added to standard colonoscopy detected 13.2 percent more polyps than colonoscopy alone, including 11 percent additional adenomas (precancerous polyps). A second study examined endoscopist experience using TER and its impact on polyp detection rates, concluding that polyp detection rates improved significantly with TER.

19 Mar 2010

Providence receives U.S. patent for CPMMS

Providence today announces the receipt of a United States Patent for the Comprehensive Particulate Matter Measurement System (CPMMS) and the Methodology for its Use. Yousheng Zeng, PhD, PE, a principal of Providence, is the inventor of this system. Dr. Zeng explains, "Unlike current methods of monitoring air-borne particulate matter (PM), the CPMMS monitors the portion of PM that can reach and deposit in a human respiratory system."

19 Mar 2010

New report on the state of U.S. mobile health market

CSMG, the strategy division of TMNG Global, a leading provider of professional services, products and services to the converging communications, media and entertainment industries, today released its report on the state of the U.S. mobile health market, entitled: mHealth: Taking the Pulse.

19 Mar 2010

Mini-laboratory: IVD platform to be presented at Analytica trade show

Many illnesses can be reliably diagnosed through laboratory tests, but these in vitro analyses often use up valuable time. A system developed by Fraunhofer research scientists, which can carry out complex analyses on the spot, will soon be ready for the market.

19 Mar 2010

Fraunhofer FIT to present IMIKRID and automated protein-level microscope system at HANNOVER MESSE

Proteins, the cellular building blocks, can be visualized and analyzed in great detail today. Here, Fraunhofer FIT presents a fully automated high-performance microscope. One of its diagnostic applications will be to study the complex interactions of proteins between cells. In tumor diagnostics our microscope allows to classify slightly different types of tumors more precisely and to fine-tune therapy accordingly.

19 Mar 2010

Global halt on Molybdenum-99 production: Discussion of implications

Discuss the severe Tc-99m shortage that will occur over a two-week period when cancer, heart and brain disease patients will experience delayed imaging tests because of a worldwide halt on Molybdenum-99 production

19 Mar 2010

CryoLife responds to Medafor's allegation on repudiation of exclusive distribution agreement

CryoLife, Inc., an implantable biological medical device and cardiovascular tissue processing company, today responded to Medafor's allegation that it has repudiated the Exclusive Distribution Agreement between the two companies.

19 Mar 2010

FDA categorizes Nanosphere's RVNATSP assay on Verigene SP System as "Moderate Complexity"

Nanosphere, Inc., a leader in the development and commercialization of advanced molecular diagnostics systems, received notification from the U.S. Food and Drug Administration (FDA) that its respiratory virus panel (RVNATSP) performed on the Verigene SP System has been categorized as "Moderate Complexity" under the Clinical Laboratory Improvement Amendments of 1988 (CLIA).

19 Mar 2010

Researchers use optogenetics technology to troubleshoot neural circuits

Recently, brain researchers have gained a powerful new way to troubleshoot neural circuits associated with depression, Parkinson's disease and other conditions in small animals such as rats. They use an optogenetics technology, invented at Stanford University, that precisely turns select brain cells on or off with flashes of light. Although useful, the optogenetics tool set has been limited.

19 Mar 2010

FDA approves expanded indication for Boston Scientific's CRT-Ds

Boston Scientific Corporation today announced that the Circulatory System Devices Panel of the U.S. Food and Drug Administration (FDA) has unanimously recommended approval of an expanded indication for its cardiac resynchronization therapy defibrillators (CRT-Ds), including the COGNIS® CRT-D. The panel recommended the expansion include the majority of the studied population of the landmark MADIT-CRT clinical trial, which evaluated the ability of these devices to slow the progression of heart failure in patients with asymptomatic or mild heart failure.

19 Mar 2010

Advaxis publishes new findings on Listeria-derived ActA anti-cancer component

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, has published new research findings on ActA as a potential, anti-cancer component and a new complement to the Company’s evolving proprietary Listeria technology platform.

19 Mar 2010

Physician scientists present new findings on aspirin therapy, atrial fibrillation drug therapy and LVAD

Physician scientists from the Cedars-Sinai Heart Institute presented new findings on the effectiveness of routine aspirin therapy for preventing heart disease, a drug therapy for atrial fibrillation and the role left ventricular assist devices may play in weight reduction for obese patients with chronic end-stage heart failure who are considered for heart transplantation.

19 Mar 2010

BioSense Technologies' Z-Sense Differential Impedance Sensing diagnostic system rapidly identifies drug susceptibility

BioSense Technologies, a pioneer in the development of diagnostic systems for rapid drug susceptibility testing, announced today that it presented key scientific findings at the National Foundation for Infection Disease 2010 Annual Conference on Antimicrobial Resistance, held in Bethesda, MD in early February.

19 Mar 2010

BioImagene's Virtuoso software integrated with anatomic pathology LIS

BioImagene, Inc., the leading provider of end-to-end digital pathology solutions, announced the integration of Virtuoso™, BioImagene’s digital pathology workflow software, with several market-leading anatomic pathology laboratory information systems.

From Elekta 19 Mar 2010

Atritech to initiate confirmatory study of WATCHMAN LAA Closure Device

Atritech, Inc., an emerging medical device company, announced today that it has obtained clarity from the U.S. Food and Drug Agency on the regulatory path towards full approval of its WATCHMAN® Left Atrial Appendage Closure Technology in the United States.

19 Mar 2010